The new network study is launched to evaluate the risk of schizophrenia in ACE inhibitor users compared with users of other antihypertensives.
CEEAMOS(Comparative Estimation of the Effects of Anti-hypertensive Medications on the Occurrence of Schizophrenia)
Rationale: Schizophrenia is a mental disorder that affects about 1 percent of the world’s population and a severe disorder which leads to functional deterioration. Genetic findings have been considered to play important roles in schizophrenia occurrence. Recently, it is reported that antihypertensive target gene was associated with schizophrenia risk. Specifically, the results for ACE messenger RNA and protein related to ACE inhibitor were shown. However real-world evidence of schizophrenia risk in relation with antihypertensive medications is scarce.
Objectives: We aim to evaluate the comparative risk of incident schizophrenia in patients exposed to antihypertensive drugs.
We will conduct systematic, multinational study to estimate the relative risk of outcomes (incident schizophrenia or incident schizophrenia requiring ER visit) in antihypertensive medication cohort (ACE inhibitor, Angiotensin receptor blockers, and Thiazide). We will compare the target cohort with the comparator cohort for the hazards of outcome during the time-at-risk by applying a cox proportional hazards model after propensitiy score adjustment.
Before staring the study, we want you to execute diagnostics package to validate feasibility of the study in each site.
The package is available at here
Please let me know if you have further questions.
Contacts of study leaders
Dong Yun Lee: email@example.com
Seng Chan You: firstname.lastname@example.org